Advertisement

Overview of Treatment Options for Adrenocortical Carcinoma

  • Gary D. Hammer
Chapter

Abstract

Complete surgical excision is the only treatment option for adrenocortical carcinoma (ACC), which provides the potential for cure. Nonetheless, the 5-year survival of patients following intent-to-cure surgery ranges between 32 and 48% [1–4]. For incidentally identified lesions that are suspected of being ACC, careful surgical judgment must be applied regarding the operative approach (laparoscopic vs. open exploration) [5].

Keywords

Adrenocortical Carcinoma Complete Surgical Excision Hormone Excess Report Response Rate Tumor Spillage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Crucitti F et al (1996) The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 119(2):161–170Google Scholar
  2. 2.
    Lee JE et al (1995) Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118(6):1090–1098CrossRefPubMedGoogle Scholar
  3. 3.
    Icard P et al (1992) Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 112(6):972–979 [discussion: 979–980]PubMedGoogle Scholar
  4. 4.
    Zografos GC et al (1994) Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol 55(3):160–164CrossRefPubMedGoogle Scholar
  5. 5.
    Saunders BD, Doherty GM (2004) Laparoscopic adrenalectomy for malignant disease. Lancet Oncology 5(12):718–726CrossRefPubMedGoogle Scholar
  6. 6.
    Dackiw AP et al (2001) Adrenal cortical carcinoma. World J Surg 25(7): 914–26Google Scholar
  7. 7.
    Cobb WS et al (2005) Laparoscopic adrenalectomy for malignancy. Am J Surg 189(4):405–411CrossRefPubMedGoogle Scholar
  8. 8.
    Gonzalez RJ et al (2005) Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 138(6):1078–1085 [discussion: 1085–6]CrossRefPubMedGoogle Scholar
  9. 9.
    Harrison LE et al (1999) Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 134(2):181–185CrossRefPubMedGoogle Scholar
  10. 10.
    Allolio B, Fassnacht M (2006) Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91(6):2027–2037CrossRefPubMedGoogle Scholar
  11. 11.
    Ng L, Libertino JM (2003) Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169(1):5–11CrossRefPubMedGoogle Scholar
  12. 12.
    Schteingart DE et al (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12(3):667–680CrossRefPubMedGoogle Scholar
  13. 13.
    Icard P et al (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25(7):891–897CrossRefPubMedGoogle Scholar
  14. 14.
    Luton JP et al (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322(17):1195–201Google Scholar
  15. 15.
    Macfarlane DA (1958) Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 23(3):155–186Google Scholar
  16. 16.
    Grondal S et al (1990) Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol 16(6):500–506PubMedGoogle Scholar
  17. 17.
    Wajchenberg BL et al (2000) Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88(4):711–736CrossRefPubMedGoogle Scholar
  18. 18.
    Hogan TF et al (1980) A clinical and pathological study of adrenocortical carcinoma: therapeutic implications. Cancer 45(11):2880–2883CrossRefPubMedGoogle Scholar
  19. 19.
    Haak HR et al (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69(5):947–951PubMedGoogle Scholar
  20. 20.
    Baudin E et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92(6):1385–1392CrossRefPubMedGoogle Scholar
  21. 21.
    van Slooten H et al (1984) The treatment of adrenocortical carcinoma with o,p’-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20(1):47–53CrossRefPubMedGoogle Scholar
  22. 22.
    Heilmann P et al (2001) Therapy of the adrenocortical carcinoma with Lysodren (o,p’-DDD): Therapeutic management by monitoring o,p’-DDD blood levels. Med Klin (Munich) 96(7):371–377Google Scholar
  23. 23.
    Venkatesh S et al (1989) Adrenal cortical carcinoma. Cancer 64(3): 765–769CrossRefPubMedGoogle Scholar
  24. 24.
    Schteingart DF et al (1982) Treatment of adrenal carcinomas. Arch Surg 117(9):1142–1146PubMedGoogle Scholar
  25. 25.
    Berruli A et al (2005) Adjuvant mitotane therapy for adreno-cortical carcinoma (abstract). J Clin Oncol 23(16S, part 1):4570Google Scholar
  26. 26.
    Dickstein G et al (1998) Is there a role for low doses of mitotane (o,p’- DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 83(9):3100–3103CrossRefPubMedGoogle Scholar
  27. 27.
    Vassilopoulou-Sellin R et al (1993) Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71(10):3119–3123CrossRefPubMedGoogle Scholar
  28. 28.
    Zhao J, Speel EJ et al (1999) Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am J Pathol 155(4):1039–1045PubMedGoogle Scholar
  29. 29.
    Kjellman M et al (1996) Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 56(18):4219–4223PubMedGoogle Scholar
  30. 30.
    Hutter AM Jr, Kayhoe DE (1996) Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 41(4):572–580CrossRefGoogle Scholar
  31. 31.
    Schulick RD, Brennan MF (1999) Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6(8):719–726CrossRefPubMedGoogle Scholar
  32. 32.
    Fassnacht M et al (2006) Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91(11):4501–4504CrossRefPubMedGoogle Scholar
  33. 33.
    Pommier RF, Brennan MF (1992) An eleven-year experience with adrenocortical carcinoma. Surgery 112(6):963–970 [discussion: 970–971]PubMedGoogle Scholar
  34. 34.
    Bertagna C, Orth DN (1981) Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 71(5):855–875Google Scholar
  35. 35.
    Stojadinovic A et al (2002) Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20(4):941–950CrossRefPubMedGoogle Scholar
  36. 36.
    Hutter AM Jr, Kayhoe DE (1996) Adrenal cortical carcinoma. Results of treatment with o,p’DDD in 138 patients. Am J Med 41(4):581–592.CrossRefGoogle Scholar
  37. 37.
    Lubitz JA et al (1973) Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223(10):1109–1112CrossRefPubMedGoogle Scholar
  38. 38.
    Decker RA et al (1991) Eastern Cooperative Oncology Group study 1879: mitotane and Adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110(6):1006–1013PubMedGoogle Scholar
  39. 39.
    Haak HR et al (1991) Prolonged bleeding time due to mitotane therapy. Eur J Cancer 27(5):638–641CrossRefPubMedGoogle Scholar
  40. 40.
    Henley DJ et al (1983) Adrenal cortical carcinoma—a continuing challenge. Surgery 94(6):926–931PubMedGoogle Scholar
  41. 41.
    Kasperlik-Zaluska AA (2000) Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 33(10):1191–1196CrossRefPubMedGoogle Scholar
  42. 42.
    Schlumberger M et al (1991) 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67(12):2997–3000CrossRefPubMedGoogle Scholar
  43. 43.
    van Slooten H, van Oosterom AT (1983) CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 67(4):377–379PubMedGoogle Scholar
  44. 44.
    Williamson SK et al (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88(5):1159–1165CrossRefPubMedGoogle Scholar
  45. 45.
    Baudin E et al (2002) Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma. Ann Oncol 13(11):1806–1809CrossRefPubMedGoogle Scholar
  46. 46.
    La Rocca RV et al (1990) Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 71(2):497–504CrossRefPubMedGoogle Scholar
  47. 47.
    Bonacci R et al (1998) Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM. Br J Cancer 78(4):546–549Google Scholar
  48. 48.
    Bukowski RM et al (1993) Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 11(1): 161–165PubMedGoogle Scholar
  49. 49.
    Berruti A et al (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12(3):657–666CrossRefPubMedGoogle Scholar
  50. 50.
    Khan TS et al (2000) Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11(10): 1281–1287CrossRefPubMedGoogle Scholar
  51. 51.
    Abraham J et al (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94(9):2333–2343CrossRefPubMedGoogle Scholar
  52. 52.
    Berruti A et al (1998) Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 83(10):2194–2200CrossRefPubMedGoogle Scholar
  53. 53.
    Koschker AC et al (2006) Adrenocortical carcinoma – improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes 114(2):45–51CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Endocrine Oncology Program – Comprehensive Cancer Center, Department of Internal Medicine – Division of Metabolism, Endocrinology & Diabetes, Department of Molecular & Integrative Physiology, Department of Cell & Developmental BiologyUniversity of MichiganAnn ArborUSA

Personalised recommendations